Efficacy and safety of systemic recombinant interferon‐alpha in Behcet's disease

Authors:

Abstract
Georgiou S, Monastirli A, Pasmatzi E, Gartaganis S, Goerz G, Tsambaos D (Departments of Dermatology and Ophthalmology, University of Patras, Greece and the Department of Dermatology, Heinrich‐Heine University of Düsseldorf, Germany). Efficacy and safety of systemic recombinant interferon‐alpha in Behcet's disease. J Intern Med 1998; 243: 367–72.Objectives: To evaluate the therapeutic efficacy and safety of systemic recombinant interferon α‐2a (IFN ‐α) in patients with Behcet's disease (BD) and to determine the incidence of episodes in complete responders during the one‐year pretreatment period and follow‐up.Design: An open clinical study.Setting: Departments of Dermatology and Ophthalmology, University of Patras, Greece and Department of Dermatology, Heinrich‐Heine University of Düsseldorf, Germany.Subjects: Twelve patients (aged 23–52 years) with active BD who had previously been unsuccessfully treated with systemic steroids and/or immunosuppressives.Interventions: IFN‐α was administered subcutaneously at a dose of 6 × 106 IU per day 3 times per week for 2 months.Main outcome measures: Change of area or number of mucocutaneous lesions, grading score for thrombophlebitis and ocular inflammation, haematological and biochemical parameters and number of episodes during the pretreatment period and the follow‐up. Evaluation of IFN‐α side effects.Results: Nine patients (75.0%) revealed a complete remission, two (16.6%) a partial remission and one patient (8.3%) showed no response. During the follow‐up in five out of the nine complete responders (55.5%) no episodes of BD were seen, whereas, the other four patients (44.5%) had 1–2 episodes, as compared to 5–8 and 5–12 episodes, respectively, during the pretreatment period. An influenza‐like syndrome (fever, nausea and myalgias) appeared during the early phase of therapy in all (but one) patients. No patient had to discontinue IFN‐α because of intolerance.Conclusions: Subcutaneous human recombinant interferon α‐2a appears to be an effective and fairly well tolerated therapy for BD.

This publication has 22 references indexed in Scilit: